Immix Biopharma, Inc. (IMMX)
NASDAQ: IMMX · Real-Time Price · USD
2.350
-0.140 (-5.62%)
At close: Jun 13, 2025, 4:00 PM
2.320
-0.030 (-1.28%)
After-hours: Jun 13, 2025, 7:56 PM EDT

Immix Biopharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020 2019
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Selling, General & Admin
11.7511.387.414.021.230.21
Upgrade
Research & Development
10.0211.298.744.20.130.25
Upgrade
Operating Expenses
21.7722.6716.148.221.350.45
Upgrade
Operating Income
-21.77-22.67-16.14-8.22-1.35-0.45
Upgrade
Interest Expense
----0-0.18-0.1
Upgrade
Interest & Investment Income
0.91.020.57---
Upgrade
Other Non Operating Income (Expenses)
-----22.76-0.57
Upgrade
EBT Excluding Unusual Items
-20.87-21.66-15.57-8.22-24.29-1.13
Upgrade
Other Unusual Items
-----0.09-
Upgrade
Pretax Income
-20.87-21.66-15.57-8.22-24.38-1.13
Upgrade
Income Tax Expense
0.040.040.030.010.010.02
Upgrade
Earnings From Continuing Operations
-20.91-21.7-15.6-8.23-24.38-1.15
Upgrade
Minority Interest in Earnings
0.010.080.17---
Upgrade
Net Income
-20.9-21.61-15.43-8.23-24.38-1.15
Upgrade
Net Income to Common
-20.9-21.61-15.43-8.23-24.38-1.15
Upgrade
Shares Outstanding (Basic)
3028171443
Upgrade
Shares Outstanding (Diluted)
3028171443
Upgrade
Shares Change (YoY)
51.33%63.11%24.87%278.13%8.82%-
Upgrade
EPS (Basic)
-0.70-0.76-0.89-0.59-6.64-0.34
Upgrade
EPS (Diluted)
-0.70-0.76-0.89-0.59-6.64-0.34
Upgrade
Free Cash Flow
-13.4-15.77-11.42-7.41-1.59-0.4
Upgrade
Free Cash Flow Per Share
-0.45-0.56-0.66-0.53-0.43-0.12
Upgrade
EBITDA
-21.7-22.64-16.14-8.22-1.35-0.45
Upgrade
D&A For EBITDA
0.070.030.01000
Upgrade
EBIT
-21.77-22.67-16.14-8.22-1.35-0.45
Upgrade
Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q